New awards of $300 million for Quinvaxem® bringing total value up to
$800 million
(Thomson Reuters ONE) - Leiden, The Netherlands (17 August, 2009) - Dutch biopharma companyCrucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) todayannounced that a large supranational organization has awarded thefirst portion of new contracts worth $300 million for supplies ofCrucell's Quinvaxem® paediatric vaccine. The new contracts are thelargest ever received by Crucell and cover the period 2010-2012, withthe initial awarded amount expected to grow even further over thosethree years.These contracts are in addition to the $500 million obtained over thetender period 2007-2009, and support the superior quality andreliability of Crucell's fully-liquid pentavalent vaccine. They bringthe total value of contracts awarded since the launch of Quinvaxem®at the end of 2006 to $800 million. During the first tender round in2006, Crucell was initially awarded $230 million (Dec 2006) andreceived additional incremental awards of $130 million and $140million in May and September, 2008, respectively."This new award for the period 2010-2012 emphasizes Crucell'sposition as a leading supplier of important vaccines. We are veryproud that by means of our pentavalent vaccine we are able to savelives by making a significant contribution to children's vaccinationprograms in the developing world," said Ronald Brus, Crucell's ChiefExecutive Officer.Following the WHO prequalification in September 2006, the combinationfully liquid pentavalent vaccine was made available to supranationalpurchasing organizations. Supranational organizations are majorcustomers for combination vaccines, which are used in largevaccination programs in developing countries.Quinvaxem® is a fully liquid vaccine combining antigens forprotection against five potentially deadly childhood diseases:diphtheria, tetanus, pertussis (whooping cough), hepatitis B, andHaemophilus influenzae type B (hib). As the first internationallyavailable fully liquid vaccine containing all five of these antigens,Quinvaxem® offers major healthcare advantages, particularly incountries with a challenging infrastructure and hygiene problems.About CrucellCrucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is aglobal biopharmaceutical company focused on research development,production and marketing of vaccines, proteins and antibodies thatprevent and/or treat infectious diseases. Its vaccines are sold inpublic and private markets worldwide. Crucell's core portfolioincludes a vaccine against hepatitis B, a fully-liquid vaccineagainst five important childhood diseases and a virosome-adjuvantedvaccine against influenza. Crucell also markets travel vaccines, suchas the only oral anti-typhoid vaccine, an oral cholera vaccine andthe only aluminum-free hepatitis A vaccine on the market. The Companyhas a broad development pipeline, with several product candidatesbased on its unique PER.C6® production technology. The Companylicenses its PER.C6® technology and other technologies to thebiopharmaceutical industry. Important partners and licensees includeDSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck &Co. Crucell is headquartered in Leiden, the Netherlands, withsubsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the U.S.The Company employs over 1000 people. For more information, pleasevisit www.crucell.com.Forward-looking statementsThis press release contains forward-looking statements that involveinherent risks and uncertainties. We have identified certainimportant factors that may cause actual results to differ materiallyfrom those contained in such forward-looking statements. Forinformation relating to these factors please refer to our Form 20-F,as filed with the U.S. Securities and Exchange Commission on April22, 2009, in the section entitled 'Risk Factors'. The Companyprepares its financial statements under International FinancialReporting Standards (IFRS).For further information please contact:Oya YavuzVice PresidentCorporate Communications & Investor RelationsTel: +31-(0)71-519 7064ir(at)crucell.comhttp://hugin.info/132631/R/1335043/317161.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 17.08.2009 - 07:45 Uhr
Sprache: Deutsch
News-ID 4749
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 387 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New awards of $300 million for Quinvaxem® bringing total value up to
$800 million"
steht unter der journalistisch-redaktionellen Verantwortung von
Crucell N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
